HanAll Biopharma Opens Applications for 2024 Pharmaceutical Industry Fellowship Program Targeting Indonesian Physicians
2024.03.18

 - Applications for Indonesian physicians are now open until April 9, 2024, at 23:59.

 

- Presents medical affairs as a new rotation in collaboration with Daewoong Group.

 

- The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various stages of the drug development process.

 


HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company dedicated to advancing healthcare through innovation and excellence in drug development, opens applications for its prestigious Fellowship Program. 


Tailored to offer extensive training across diverse aspects of the pharmaceutical sector, this program presents a distinctive opportunity for Indonesian physicians to immerse themselves in dynamic global environments. The application period for the program will run from March 14 to April 9, 2024.

 

The HanAll Pharmaceutical Industry Fellowship Program aims to cultivate well-rounded physicians by offering rotations in four key areas of drug development: Clinical and Pre-clinical, Operations and Regulatory Affairs, Medical Affairs, and Business Development.

 

This year, in collaboration with Daewoong Group, the program introduces medical affairs as a new rotation. All participants in this program will operate under a hybrid model, spending approximately six months at the Jakarta office and the remainder working from home.

 

Selected participants will play a crucial role in providing insights for pre-clinical and translational work, contributing to clinical development plans, fostering relationships with scientific experts including Key Opinion Leaders, and tracking scientific developments in relevant therapeutic areas such as neurology, oncology, immunology and ophthalmology.

 

Interested candidates must hold an MD degree from Indonesia and demonstrate strong written and oral English communication skills to apply to this program. A keen interest in drug development, including preclinical and clinical phases, is essential, along with a curiosity for learning from different cultures. While experience in immunology, neurology, ophthalmology, or oncology is preferred, it is not mandatory. Candidates must also commit to reside in Indonesia throughout the two-year duration of the fellowship program.

 

Medical doctors with various competencies, including executive communication, problem-solving, and cross-cultural awareness, are encouraged to apply. Prospective fellows should exhibit proactive, dynamic personalities while also being team players, demonstrating agility and resilience in their approach.

 

“This program provides an eye-opening experience, introducing me to innovative career paths beyond traditional medical practice that I had never considered before. As a medical doctor, this fellowship has not only provided me with invaluable insights and knowledge not covered in medical school but also offered me international exposure through mentorship, broadening my perspective on the global healthcare landscape and the diverse opportunities within the sector,” commented Dr. Soraya Arifa, a participant in the program in 2022.

 

To apply, applicants are required to fill out the application form on the VIVIDAPP website, which is accessible by clicking on the banner on HanAll’s official website. The application form requires attaching a CV, an introduction video, and transcripts. Successful applicants will benefit from a hybrid work environment, annual paid leave, severance pay, experienced mentorship, and comprehensive employee benefits, including insurance.